Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.
You may also be interested in...
Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)
R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.
Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)
R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.